pca commentary - parp inhibition w/ olaparib: potential new indication for first-line mcrpc therapy
Published 1 year ago • 254 plays • Length 12:36Download video MP4
Download video MP3
Similar videos
-
16:22
role of parp inhibitors in prostate cancer
-
2:34
listen: pca commentary december 2019 interview with dr. ed weber
-
7:18
updates in parp inhibition and germline testing in prostate cancer
-
8:11
pca commentary november 2021
-
13:09
pca commentary: metastatic hormone sensitive prostate cancer (mhspc): many treatment options
-
10:25
parpi in mcrpc
-
33:19
castration resistant prostate cancer - developments and challenges from 2020
-
5:33
pca commentary for october 2021: therapy of the primary tumor in newly diagnosed mhspc
-
9:51
parp in combination with standard of care treatment
-
12:24
the role of targeting dna repair with parp
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
42:42
round-table discussion on parp inhibitor
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
21:53
identifying mutations and optimizing use of parp inhibitors
-
4:12
parp inhibitors
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas
-
4:55
parp inhibitors in castrate-resistant prostate cancer
-
6:31
understanding the side effects of parp inhibitors